Global Stroke Prevention in Atrial Fibrillation Market 2017-2024: Survey of 213 Cardiologists in the US, Japan, and Five Major EU markets Sheds Light on Prescribing Trends in SPAF.
Atrial fibrillation is the most common chronic cardiac arrhythmia, and is usually associated with other cardiovascular diseases. Atrial fibrillation is characterized by an irregular heartbeat, where the atria may not contract properly. While the disease is not considered life-threatening in itself, atrial fibrillation is one of the leading causes of stroke, with the disease conferring a fivefold increased risk.
Market Snapshot
The approval of antidotes for the novel oral anticoagulants will play a major role in increasing uptake of these drugs.
Survey of 213 cardiologists in the US, Japan, and five major EU markets sheds light on prescribing trends in SPAF.
Diagnosed prevalent cases of atrial fibrillation are estimated to increase by more than 40% during the forecast period.
Eliquis's low bleeding risk and strong efficacy results in SPAF patients will likely help to increase the uptake of the medication.
Drug developers will need to identify reversal agents in order for pipeline medications to be able to compete with marketed drugs.
EU payers limit use due to high cost, while US payers support uptake.
Key Topics Covered:
Forecast: Stroke Prevention In Atrial Fibrillation
Market Overview And Trends
Market Definition And Methodology
Eliquis (Apixaban)
Pradaxa (Dabigatran)
Savaysa (Edoxaban)
Xarelto (Rivaroxaban)
Treatment: Stroke Prevention In Atrial Fibrillation
Primary Research Methodology
Disease Definition And Diagnosis
Current Treatment Options
Prescribing Trends
Epidemiology: Atrial Fibrillation
Disease Background
Methodology
Forecast
Epidemiologist Insight
Strengths And Limitations
Bibliography
Appendix: Additional Sources
Marketed Drugs: Stroke Prevention In Atrial Fibrillation
Product Overview
Product Profile: Eliquis
Product Profile: Pradaxa
Product Profile: Savaysa
Product Profile: Xarelto
Noacs Pricing, Reimbursement, And Access
Regulatory Labels
Global Payer And Key Opinion Leader Insights
Us Pricing
Us Reimbursement
Japan
Pricing In The Five Major Eu Markets
France
Germany
Italy
Spain
UK
Methodology
Pipeline: Stroke Prevention In Atrial Fibrillation
Dr. Ryan M. Jouett, DDS, LVIM, FICOI has become one of only 25 Master Dentists in the world as a graduate of the Las Vegas Institute for Advanced Dental Studies in Las Vegas, NV....
Endo, Inc. ("Endo" or the "Company"), a newly formed entity, today announced that it has successfully completed the previously announced acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's...
Solventum announced today that it will release carve-out financial results for the first quarter 2024 before the market opens on May 9, 2024. The earnings press release and accompanying materials will be available on the company's website at...
Amped Fitness®, the independently-owned and rapidly-expanding fitness franchise, recently announced the Grand Opening of their Tallahassee, Florida location, set for May 20th, 2024....
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2024 financial results on Tuesday, May 7, 2024, after the U.S. financial markets...
Dr. Eric Nepute, a distinguished healthcare professional and entrepreneur, is pleased to announce the establishment of the Eric Nepute Grant for Medical Students. Valued at $1,000, this grant aims to support aspiring medical professionals who exhibit...